AR116548A1 - Anticuerpos contra bcma soluble - Google Patents
Anticuerpos contra bcma solubleInfo
- Publication number
- AR116548A1 AR116548A1 ARP190102761A ARP190102761A AR116548A1 AR 116548 A1 AR116548 A1 AR 116548A1 AR P190102761 A ARP190102761 A AR P190102761A AR P190102761 A ARP190102761 A AR P190102761A AR 116548 A1 AR116548 A1 AR 116548A1
- Authority
- AR
- Argentina
- Prior art keywords
- sbcma
- monoclonal antibody
- multiple myeloma
- binding
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente se refiere a anticuerpos que se unen a BCMA soluble (sBCMA). Además, la presente se refiere a un sistema de detección que comprende dichos anticuerpos. Los anticuerpos o el sistema de detección pueden usarse para detectar o cuantificar sBCMA, para diagnosticar una enfermedad asociada con sBCMA, para estratificar pacientes, monitorizar la progresión de la enfermedad y evaluar la respuesta terapéutica. Reivindicación 1: Un anticuerpo monoclonal que se une a BCMA soluble (sBCMA), donde la unión del anticuerpo a sBCMA se produce en presencia de un segundo anticuerpo monoclonal que se une a sBCMA. Reivindicación 2: El anticuerpo monoclonal de acuerdo con la reivindicación 1, donde sBCMA tiene la secuencia de aminoácidos tal como se representa en la SEQ ID Nº 34. Reivindicación 14: Un proceso para producir un anticuerpo monoclonal tal como se define en una cualquiera de las reivindicaciones 1 a 10, comprendiendo dicho proceso cultivar una célula huésped tal como se define en la reivindicación 13, en condiciones que permitan la expresión de dicho anticuerpo monoclonal y recuperar el anticuerpo monoclonal producido del cultivo. Reivindicación 15: Una composición que comprende un anticuerpo monoclonal tal como se define en una cualquiera de las reivindicaciones 1 a 10, o producido según el proceso de la reivindicación 14. Reivindicación 16: Un sistema de detección que comprende a) un primer anticuerpo monoclonal que se une a sBCMA, y b) un segundo anticuerpo monoclonal que se une a sBCMA, donde la unión del primer anticuerpo monoclonal a sBCMA se produce en presencia del segundo anticuerpo monoclonal que se une a sBCMA, y/o donde la unión del segundo anticuerpo monoclonal a sBCMA se produce en presencia del primer anticuerpo monoclonal que se une a sBCMA. Reivindicación 31: El uso de una cualquiera de las reivindicaciones 25, 29 ó 30 o el método de una cualquiera de las reivindicaciones 26 - 30, donde la enfermedad se selecciona del grupo que consiste en mieloma múltiple, mieloma múltiple recidivante y/o refractario, mieloma múltiple de cadena pesada, mieloma múltiple de cadena ligera, mieloma extramedular (plasmacitoma extramedular, mieloma múltiple extramedular), plasmacitoma, leucemia de células plasmáticas, macroglobulinemia de Waldenström (linfoma linfoplasmacítico), mieloma latente (mieloma múltiple latente), leucemia linfocítica crónica (CLL), linfoma primario del SNC (PCNSL), y linfoma no Hodgkin de linfocitos B (B-NHL).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862738997P | 2018-09-28 | 2018-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR116548A1 true AR116548A1 (es) | 2021-05-19 |
Family
ID=68296657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102761A AR116548A1 (es) | 2018-09-28 | 2019-09-27 | Anticuerpos contra bcma soluble |
Country Status (11)
Country | Link |
---|---|
US (1) | US11505614B2 (es) |
EP (1) | EP3856781A1 (es) |
JP (1) | JP2022501389A (es) |
KR (1) | KR20210068408A (es) |
CN (1) | CN112703204A (es) |
AR (1) | AR116548A1 (es) |
BR (1) | BR112021005669A2 (es) |
MA (1) | MA53732A (es) |
TW (1) | TW202028239A (es) |
UY (1) | UY38393A (es) |
WO (1) | WO2020069303A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3819007A1 (en) * | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1985A (en) | 1841-02-18 | Charles m | ||
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
DE69131780T2 (de) | 1991-03-11 | 2000-11-16 | Univ Georgia Res Foundation At | Klonierung und expression der luziferase aus renilla |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
CA2169298A1 (en) | 1993-09-10 | 1995-03-16 | Martin Chalfie | Uses of green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
ATE290205T1 (de) | 1996-12-12 | 2005-03-15 | Prolume Ltd | Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen |
CA2324648C (en) | 1998-03-27 | 2013-02-26 | Prolume, Ltd. | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Cd19×cd3特異的ポリペプチドおよびその使用 |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
DE69911793T2 (de) | 1998-07-28 | 2004-08-12 | Micromet Ag | Heterominikörper |
DK1673398T3 (da) | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecifikke, deimmuniserede CD3-bindere |
BRPI0511782B8 (pt) | 2004-06-03 | 2021-05-25 | Novimmune Sa | anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor |
JP2010524851A (ja) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
HUE038225T2 (hu) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák |
US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
WO2015048272A1 (en) | 2013-09-25 | 2015-04-02 | Amgen Inc. | V-c-fc-v-c antibody |
EP3029068A1 (en) * | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
JP6901493B2 (ja) * | 2015-11-13 | 2021-07-14 | アメリカ合衆国 | 抗bcmaポリペプチド及びタンパク質 |
ES2898329T3 (es) * | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
MA43955B1 (fr) | 2016-02-03 | 2022-02-28 | Amgen Inc | Anticorps anti-bcma et anti-cd3 bispécifiques de format bite |
-
2019
- 2019-09-27 EP EP19790922.9A patent/EP3856781A1/en active Pending
- 2019-09-27 AR ARP190102761A patent/AR116548A1/es unknown
- 2019-09-27 KR KR1020217008023A patent/KR20210068408A/ko active Search and Examination
- 2019-09-27 TW TW108135221A patent/TW202028239A/zh unknown
- 2019-09-27 UY UY0001038393A patent/UY38393A/es unknown
- 2019-09-27 US US16/585,318 patent/US11505614B2/en active Active
- 2019-09-27 JP JP2021516763A patent/JP2022501389A/ja active Pending
- 2019-09-27 WO PCT/US2019/053433 patent/WO2020069303A1/en active Search and Examination
- 2019-09-27 MA MA053732A patent/MA53732A/fr unknown
- 2019-09-27 BR BR112021005669-6A patent/BR112021005669A2/pt unknown
- 2019-09-27 CN CN201980056983.1A patent/CN112703204A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
UY38393A (es) | 2020-03-31 |
JP2022501389A (ja) | 2022-01-06 |
BR112021005669A2 (pt) | 2021-06-22 |
WO2020069303A1 (en) | 2020-04-02 |
CN112703204A (zh) | 2021-04-23 |
US11505614B2 (en) | 2022-11-22 |
TW202028239A (zh) | 2020-08-01 |
EP3856781A1 (en) | 2021-08-04 |
MA53732A (fr) | 2022-01-05 |
US20200102398A1 (en) | 2020-04-02 |
KR20210068408A (ko) | 2021-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Koutsakos et al. | Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity | |
PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
AU2018258190A1 (en) | Methods and apparatus that increase sequencing-by-binding efficiency | |
EA201692157A1 (ru) | Синтез двухцепочечных нуклеиновых кислот | |
CR20190009A (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso. | |
JP2016026303A5 (es) | ||
BR112017003582A2 (pt) | anticorpos, composições e usos | |
PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
HRP20211541T1 (hr) | Anti-asic1 antitijela i njihove upotrebe | |
WO2018167141A3 (en) | Target detection using a monovalent antibody | |
PE20190415A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos | |
AU2018274704A1 (en) | Assay for plasma cell associated disease | |
AR090410A1 (es) | Anticuerpos mutantes y conjugacion de los mismos | |
AR109857A1 (es) | Anticuerpos anti-chikv y usos de éstos | |
PE20180576A1 (es) | ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL ANTIGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, UTILES PARA LA DETECCION Y EL DIAGNOSTICO DE LA INFECCION CAUSADA POR VRSh | |
AR116548A1 (es) | Anticuerpos contra bcma soluble | |
PE20130526A1 (es) | Componentes de la pared de celulas de levadura y deteccion de los mismos | |
ES2722900T3 (es) | Portaobjetos para micromatrices y método para detectar algas tóxicas | |
MX2022004737A (es) | Anticuerpos anti-nogo-a novedosos. | |
CO2017006157A2 (es) | Método de manufactura de proteína |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |